These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 19167603)

  • 21. Health care resource utilization following initiation of a triptan: a retrospective claims analysis.
    Messali A; Owens G; Bloudek L; Kori S; Cole A; Chia J
    J Manag Care Spec Pharm; 2014 Apr; 20(4):368-75. PubMed ID: 24684641
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical advances in the preventive treatment of migraine.
    Mannix LK
    Acta Neurol Taiwan; 2004 Dec; 13(4):158-69. PubMed ID: 15666691
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Costs and utilization of triptan users who receive drug prophylaxis for migraine versus triptan users who do not receive drug prophylaxis.
    Etemad LR; Yang W; Globe D; Barlev A; Johnson KA
    J Manag Care Pharm; 2005 Mar; 11(2):137-44. PubMed ID: 15766320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Determinants of prophylactic migraine therapy in Spain].
    Pascual-Gómez J; Caminero AB; Cano A; Heras-Pérez JA; Leira-Muiño R; García-Ribas G;
    Rev Neurol; 2007 Nov 1-15; 45(9):513-8. PubMed ID: 17979079
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low-dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study).
    Gupta P; Singh S; Goyal V; Shukla G; Behari M
    Headache; 2007 Mar; 47(3):402-12. PubMed ID: 17371357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patient characteristics and prescription fill patterns for allergic rhinitis medications, with a focus on montelukast, in a commercially insured population.
    Bollinger ME; Diette GB; Chang CL; Stephenson JJ; Sajjan SG; Fan T; Allen-Ramey FC
    Clin Ther; 2010 Jun; 32(6):1093-102. PubMed ID: 20637964
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Results of a 2-year retrospective cohort study of newly prescribed triptan users in European nationwide practice databases.
    Ng-Mak DS; Chen YT; Ho TW; Stanford B; Roset M
    Cephalalgia; 2012 Sep; 32(12):875-87. PubMed ID: 22833612
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topiramate prescribing patterns among medicaid patients: diagnosis, comorbidities, and dosing.
    Poston S; Dickson M; Johnsrud M; Rupnow MF; Gdovin JM; Bramley TJ; Armstrong RB
    Clin Ther; 2007 Mar; 29(3):504-18. PubMed ID: 17577471
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Topiramate in migraine prevention: evidence-based medicine from clinical trials.
    Silberstein SD
    Neurol Sci; 2004 Oct; 25 Suppl 3():S244-5. PubMed ID: 15549548
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resource use associated with topiramate in migraine prophylaxis.
    Feliu AL; Rupnow MF; Blount A; Boccuzzi SJ; Vermilyea J
    Am J Health Syst Pharm; 2007 Jul; 64(14):1483-91. PubMed ID: 17617498
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Utilization of topiramate during pregnancy and risk of birth defects.
    Green MW; Seeger JD; Peterson C; Bhattacharyya A
    Headache; 2012; 52(7):1070-84. PubMed ID: 22724387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Erenumab patient characteristics, medication adherence, and treatment patterns in the United States.
    Hines DM; Shah S; Multani JK; Wade RL; Buse DC; Bensink M
    Headache; 2021 Apr; 61(4):590-602. PubMed ID: 33594672
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validity of the adherence estimator in the prediction of 9-month persistence with medications prescribed for chronic diseases: a prospective analysis of data from pharmacy claims.
    McHorney CA; Victor Spain C; Alexander CM; Simmons J
    Clin Ther; 2009 Nov; 31(11):2584-607. PubMed ID: 20110004
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Zonisamide versus topiramate in migraine prophylaxis: a double-blind randomized clinical trial.
    Mohammadianinejad SE; Abbasi V; Sajedi SA; Majdinasab N; Abdollahi F; Hajmanouchehri R; Faraji A
    Clin Neuropharmacol; 2011; 34(4):174-7. PubMed ID: 21738025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prophylactic treatment of vestibular migraine.
    Salmito MC; Duarte JA; Morganti LOG; Brandão PVC; Nakao BH; Villa TR; Ganança FF
    Braz J Otorhinolaryngol; 2017; 83(4):404-410. PubMed ID: 27320656
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A double-blind, randomized trial of low-dose topiramate vs propranolol in migraine prophylaxis.
    Ashtari F; Shaygannejad V; Akbari M
    Acta Neurol Scand; 2008 Nov; 118(5):301-5. PubMed ID: 18713156
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparative study of the effects of low-dose topiramate versus sodium valproate in migraine prophylaxis.
    Afshari D; Rafizadeh S; Rezaei M
    Int J Neurosci; 2012 Feb; 122(2):60-8. PubMed ID: 21950578
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of MDR1, CYP2D6, and CYP2C19 gene polymorphisms with prophylactic migraine treatment response.
    Atasayar G; Eryilmaz IE; Karli N; Egeli U; Zarifoglu M; Cecener G; Taskapilioglu O; Tunca B; Yildirim O; Ak S; Tezcan G; Can FE
    J Neurol Sci; 2016 Jul; 366():149-154. PubMed ID: 27288795
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Paediatric migraine disability assessment score is a useful tool for evaluating prophylactic migraine treatment.
    Topcu Y; Hiz Kurul S; Bayram E; Sozmen K; Yis U
    Acta Paediatr; 2014 Nov; 103(11):e484-9. PubMed ID: 25048365
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Topiramate for migraine prevention in adolescents: a pooled analysis of efficacy and safety.
    Winner P; Gendolla A; Stayer C; Wang S; Yuen E; Battisti WP; Nye JS
    Headache; 2006; 46(10):1503-10. PubMed ID: 17115983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.